Alan L Mueller
Pharmacy in Salt Lake City, UT

6617358, Sep 9, 2003

Jun 2, 2000

09/587179

Manuel F. Balandrin - Sandy UT
Bradford C. VanWagenen - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Alan L. Mueller - Salt Lake City UT
Daryl Smith - Salt Lake City UT
Scott T. Moe - Salt Lake City UT

NPS Pharmaceuticals, Inc. - Salt Lake City UT

A61K 31165

514617, 514557, 514568

Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e. g. , anticonvulsant activity) useful for the treatment of neurological diseases or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacological half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

7087765, Aug 8, 2006

Mar 9, 2004

10/797355

Alan L. Mueller - Salt Lake City UT, US
Scott T. Moe - Salt Lake City UT, US

NPS Pharmaceuticals, Inc. - Salt Lake City UT

C07D 337/16, C07D 495/00, C07D 313/00, C07D 311/82, C07C 211/03

549 12, 549 26, 549354, 549388, 564355, 564360, 564361, 564363, 564379

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

6017965, Jan 25, 2000

Dec 11, 1996

8/763480

Alan L. Mueller - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Bradford C. VanWagenen - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Robert M. Barmore - Salt Lake City UT
Daryl L. Smith - Salt Lake City UT

NPS Pharmaceuticals, Inc. - Salt Lake City UT

A61K 31135, C07C21762

514649

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

7268166, Sep 11, 2007

Feb 13, 2006

11/352630

Alan L. Mueller - Salt Lake City UT, US
Scott T. Moe - Salt Lake City UT, US

NPS Pharmaceuticals, Inc. - Parsippany NJ

A61K 31/135, C07C 211/00, C07C 211/03, C07C 225/00

514648, 564315, 564316, 564319

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

2003019, Oct 23, 2003

May 2, 2003

10/429060

Manuel Balandrin - Sandy UT, US
Bradford VanWagenen - Salt Lake City UT, US
Linda Artman - Salt Lake City UT, US
Alan Mueller - Salt Lake City UT, US
Daryl Smith - Salt Lake City UT, US
Scott Moe - Boston MA, US

NPS Pharmaceuticals, Inc.

A61K031/192, A61K031/165, C07C063/33, C07C233/64

514/570000, 514/617000, 564/171000, 562/491000

Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological diseases or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacologic half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

6306912, Oct 23, 2001

Jun 7, 1995

8/483294

Alan L. Mueller - Salt Lake City UT
Bradford C. VanWagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Scott T. Moe - Salt Lake City UT
Linda D. Artman - Salt Lake City UT

NPS Pharmaceuticals, Inc. - Salt Lake City UT

A61K 31135

514648

Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.

6211245, Apr 3, 2001

Nov 4, 1998

9/186341

Alan L. Mueller - Salt Lake City UT
Scott T. Moe - Salt Lake City UT

NPS Pharmaceuticals, Inc. - Salt Lake City UT

A61K 31135, C07C21103

514653

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hyproxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

6051610, Apr 18, 2000

Feb 18, 1999

9/252433

Alan L. Mueller - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Bradford C. Van Wagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Robert M. Barmore - Salt Lake City UT

NPS Pharmaceuticals, Inc. - Salt Lake City UT

A61K 31135, C07C21135

514628

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

2004003, Feb 26, 2004

Nov 21, 2001

09/990405

Alan Mueller - Salt Lake City UT, US
Scott Moe - Salt Lake City UT, US
Manuel Balandrin - Sandy UT, US

NPS Pharmaceuticals, Inc.

A61K031/47, A61K031/44, A61K031/381, A61K031/341, A61K031/137

514/307000, 514/314000, 514/357000, 514/438000, 514/471000, 514/546000, 514/649000

The present invention features compounds active at both the serotonin reuptake site and the N-methyl-D-aspartate (NMDA) receptor and the use of such compounds for treating different disorders. Compounds having activity at the serotonin reuptake site and the NMDA receptor (“multi-active compounds”) can be used to treat different types of disorders such as depression, obsessive-compulsive disorders (OCD), sleep, disorders, sexual dysfunction, and eating disorders. Preferably, the multi-active compounds are used to treat depression.

6071970, Jun 6, 2000

Jun 7, 1995

8/485038

Alan L. Mueller - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Bradford C. VanWagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Robert M. Barmore - Salt Lake City UT

NPS Pharmaceuticals, Inc. - Salt Lake City UT

A61K 31135, C07C21103

514648

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).